


The Leading Patient Recruitment Organization (PRO) in China



The Pioneer of the Integrated Recruitment Model in China



Experience

Study Feasibility, Patient Recruitment and Retention, Site Selection, Creative Development, Site Support, Media Planning/Buying, Call-Center, Study Website, Metrics, and Reporting

Indication	Study phase	# of Patients	# of Sites	# of Study
Diabetes, Diabetes Complications	I,II,III,IV	3526	148	26
Ophthalmic Diseases	III	175	42	4
Neurological Disease	III	756	78	7
Alzheimer's Disease	I,II,III	322	60	5
Respiratory Disease	III	714	97	12
Infectious Diseases	II,III	774	81	11
Rheumatoid Diseases	III	912	71	19
Gastrointestinal Diseases	III	561	43	9
Solid tumor	I,II,III,IV	3557	112	94
Hematologic malignancies	III	375	69	22
Orphan Disease	I,III	192	24	7
Womens Health	III	1762	151	12
Cardiovascular disease	III	329	93	10

Case Study

Patient recruitment for **PD-1** drugs' clinical trials

From Jan 2017 to Apr 2019 we have successfully recruited patients with various cancer types for PD-1 clinical trials:

• HCC 305 ICF



• EC 356 ICF



• LC 598 ICF



Recruitment of T2D Patients

200 patients with T2D were recommended and screened to sign off ICF within a 8 month period




Recruitment of patients with orphan diseases

Patients with rare diseases were recommended: 11 ICF within 6 months and 23 ICF within one year for patients with Waldenstroem macroglobulinemia



SEVERAL TOP TEN PHARMA COMPANIES UTILIZE JSURE SUPPORT TO IMPROVE ENROLLMENT PERFORMANCE



Contact us:

Shanghai Office:
8th Floor, Jinhui Tower, No.8 Wuzhong Road, Shanghai, 200336
Contact person: Eason Zhu (SH)
Email: Eason.zhu@jsure.com
Mobile: (86)18001653751

Beijing Office:
9F Navigation Industrial Building, 108 Jianguo Road, Beijing, 110105
Contact person: Winni Meng (BJ)
Email: winni.meng@jsure.com
Mobile: (86)17710235108